KLUS Pharma, Inc

(No Reviews)
8 Clarke Dr #4, Cranbury, NJ 08512, USA

KLUS Pharma, Inc is located in Middlesex County of New Jersey state. On the street of Clarke Drive and street number is 8. To communicate or ask something with the place, the Phone number is (609) 662-1913. You can get more information from their website.
The coordinates that you can use in navigation applications to get to find KLUS Pharma, Inc quickly are 40.3290498 ,-74.5027992

Contact and Address

Address: 8 Clarke Dr #4, Cranbury, NJ 08512, USA
Postal code: 08512
Phone: (609) 662-1913
Website: http://www.kluspharma.com/

Opening Hours:

Monday:8:30 AM – 6:00 PM
Tuesday:8:30 AM – 6:00 PM
Wednesday:8:30 AM – 6:00 PM
Thursday:8:30 AM – 6:00 PM
Friday:8:30 AM – 6:00 PM
Saturday:Closed
Sunday:Closed

Location & routing

Get Directions

Reviews

There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about KLUS Pharma, Inc, use the form below and your opinion, advice or comment will appear in this space.

Write a Review


KLUS Pharma, Inc On the Web

Kelun Pharmaceutical Group

8 Clarke drive, Cranbury, New Jersey 08512 Tel. 609-662-1913


KLUS Pharma Inc | ZoomInfo.com

(609) 662-1913. Fax: (609) 662-1918. Website: www.kluspharma.com. More. Description: Klus Pharma, Inc. was established in 2014. Klus Pharma is a niche pharmaceutical ...


Haijun Tian | KLUS Pharma Inc | ZoomInfo.com

Klus Pharma, Inc. was established in 2014. Klus Pharma is a niche pharmaceutical company located in the Princeton area of New Jersey. We focus on generic pharmaceutical development, manufacturing, sales & marketing as well as APIs in North American...


Study of A166 in Patients With Relapsed/Refractory Cancers ...

Klus Pharma Inc. Information provided by (Responsible Party): ... 609-662-1913: Clinicaltrialinfo@kluspharma.com: Locations. Layout table for location information;


Clinical Trials Dashboard

Source: Klus Pharma Inc. Brief Summary Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.


A166 in Patients With Relapsed/Refractory Cancers Expressing ...

Overview. Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.